News | 19 May 2023
Thermo Fisher Scientific expands ImmunoCAP test availability across U.S.
Testing supporting allergy diagnosis now accessible to more people in more communities
Testing supporting allergy diagnosis now accessible to more people in more communities
These initiatives aim to improve access to healthcare for rare disease patients
The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
The company has reported total income of Rs. 604.02 crores during the period ended March 31, 2023
Concept Medical’s manufacturing arm has reduced its carbon footprint via in-house efficiency improvement programmes & green infrastructure
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
Farxiga is expected to have such a strong influence on the market due to the impressive results
The facility will have a capacity to manufacture upto 3 million tubes monthly
The company has reported total income of Rs. 149.78 crores during the period ended March 31, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Subscribe To Our Newsletter & Stay Updated
